A Phase 4 interventional study of Use of iFuse TORQ in Sacroiliac Joint Dysfunction, Sacroiliac; Fusion and Sacroiliac Disorder, sponsored by SI-BONE, Inc.. Active, not recruiting at 14 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by SI-BONE, Inc. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Arthralgia with a site in United States — 17 open to participants now, 23 under way, 4 of them phase 3. Arthralgia · United States.
Among the 106 studies in Arthralgia with a site in United States, this one is the 33rd largest by planned enrollment of the 88 interventional ones that give a count, is one of 4 that started in 2023, is one of 6 in phase 4, reaches primary completion later than 3 of the 22 other live ones, and was the 91st registered.
277 studies on the registry are indexed under Arthralgia; 54 are open to participants now.
Browse Arthralgia studies →17 of the 106 studies in Arthralgia with a site in United States are open now. Recruiting first, the newest first:
Indiana University · Sites in United States
Ages 18+
PainTEQ, LLC · Sites in United States
Ages 21+
PainTEQ, LLC · Sites in United States
Ages 21+
Weill Medical College of Cornell University · Sites in United States
Ages 18–75
Veterans Medical Research Foundation · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 35 Arthralgia studies recruiting now, 18 (51%) set no upper age limit and 16 (46%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 16 · Phase 3 20 · Phase 4 6
First in 2004; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is above the median of 73 across 218 interventional studies indexed under Arthralgia.
Median enrollment 82 across the 88 interventional studies, 144 across the 18 observational. Of the 67 that completed or were terminated, 24 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 106 have an industry lead sponsor. The 10 most frequent:
SI-BONE, Inc. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
SI-BONE, Inc. has 5 studies filed under Arthralgia — fewer than ten, so there is no comparison to draw.
7 of the studies in Arthralgia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05703178Phase 3Northwestern UniversityWeb-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia | 2026-11-30 |
| NCT05658575Phase 3Olatec Therapeutics, Inc.Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | 2026-12-31 |
| NCT05621369Sage BionetworksPsorcast Mobile Study | 2027-01-31 |
| NCT04994249Stanford UniversityDiagnostic and Prognostic Biomarkers for High-impact Chronic Pain: Development and Validation | 2027-04-25 |
| NCT07547215PainTEQ, LLCPost-Market Clinical Study Using TRAQ™ for Minimally Invasive Posterior Sacroiliac Joint Fusion | 2027-07 |
Add all 7 to your calendar (.ics) → With an account.
Among the 106 studies in Arthralgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
iFuse TORQ for the Treatment of Sacroiliac Joint Dysfunction (STACI) is a prospective, multicenter, study of SIJ fusion using the iFuse TORQ implant system.
This trial is a prospective, multicenter, study of SIJ fusion using the iFuse TORQ implant system. The goal of the trial is to demonstrate the effectiveness of the device for its intended use.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with SI joint dysfunction are treated with iFuse TORQ.
Device: Use of iFuse TORQ
Use of iFuse TORQ for the treatment of SI Joint dysfunction
Change in SI joint pain measured by numerical rating scale (NRS)
Change in SI joint pain measured by NRS (0- no pain to 10- worst pain imaginable)
Time frame: At baseline and 6 months
Improvement from baseline in SI joint (SIJ) pain
Improvement from baseline in SIJ pain as measured by numeric rating scale (0- no pain to 10- worst pain imaginable).
Time frame: At baseline, 1-, 3-, 6-, 12-, and 24-months
Improvement from baseline in disability
Improvement from baseline in disability as measured by Oswestry Disability Index
Time frame: At baseline, 1-, 3-, 6-, 12-, and 24-months
Improvement from baseline in quality of life
Improvement from baseline in aggregate quality of life and individual domains as measured by PROMIS-29.
Time frame: At baseline, 1-, 3-, 6-, 12-, and 24-months
Proportion of subjects with a complication rated as probably or definitely related to the procedure or device.
Time frame: At baseline, 1-, 3-, 6-, 12-, and 24-months
Evidence of bone binding
Evidence of bone binding to at least 50% of the porous surface area of each implanted device
Time frame: At baseline and 24 months
Proportion of treated sides showing signs of loosening of iFuse TORQ or other instrumentation
Proportion of treated sides showing signs of loosening of iFuse TORQ or other instrumentation, as evidenced by both radiopaque areas around implant plus bony reaction ("rind") near implant
Time frame: At baseline and 24 months
Proportion of iFuse TORQ implants that show evidence of device migration
Time frame: At baseline and 24 months
Proportion of iFuse TORQ implants that show breakage
Time frame: At baseline and 24 months
Ran from May 2023 to primary completion in Apr 2025, 23 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SI-BONE, Inc.